Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 pelabresib + ruxolitinib versus placebo + ruxolitinib in JAK inhibitor-naive myelofibrosis
CTR20261337Phase 3Active
- Sponsor
- Novartis
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pelabresib, ruxolitinib in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), post-essential thrombocythemia myelofibrosis (PET-MF), sponsored by Novartis. Started Jul 2026; status: active.
02
Drugs
pelabresibruxolitinib
03
Conditions
primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on CTR20261337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261337.